Pfizer Correlations

PFE Stock  USD 24.47  0.11  0.45%   
The current 90-days correlation between Pfizer Inc and Inhibrx Biosciences, is 0.28 (i.e., Modest diversification). The correlation of Pfizer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Pfizer Correlation With Market

Very weak diversification

The correlation between Pfizer Inc and DJI is 0.55 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Pfizer Inc and DJI in the same portfolio, assuming nothing else is changed.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

Moving together with Pfizer Stock

  0.69NKTR Nektar TherapeuticsPairCorr
  0.65MRK Merck CompanyPairCorr
  0.82KMDA KamadaPairCorr
  0.87CAT CaterpillarPairCorr
  0.83AXP American ExpressPairCorr
  0.78BA BoeingPairCorr
  0.85CSCO Cisco SystemsPairCorr
  0.69XOM Exxon Mobil CorpPairCorr
  0.86JPM JPMorgan ChasePairCorr
  0.84MSFT MicrosoftPairCorr
  0.85DD Dupont De NemoursPairCorr
  0.77GE GE Aerospace Earnings Call This WeekPairCorr
  0.83IBM International Business Earnings Call This WeekPairCorr
  0.74MMM 3M CompanyPairCorr

Moving against Pfizer Stock

  0.49MSB Mesabi TrustPairCorr
  0.35VZ Verizon Communications Earnings Call TomorrowPairCorr

Related Correlations Analysis

Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Risk-Adjusted Indicators

There is a big difference between Pfizer Stock performing well and Pfizer Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Pfizer's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.